Xeris Pharmaceuticals, Inc.
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1
Ending by 2030
Sep 2027
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Mar 8 to 22, 2027 · next Mar 8
- 1 fee due May 26, 2027The maintenance fee for Methods for Producing Stable Therapeutic Formulations in Aprotic Polar Solvents (US 10,485,850) comes due May 26, 2027. Unpaid by Nov 26, 2027, it lapses early.
- 1 fee due Jun 5, 2027The maintenance fee for Precipitation Resistant Small Molecule Drug Formulations (US 11,833,157) comes due Jun 5, 2027. Unpaid by Dec 6, 2027, it lapses early.
- 1 fee due Aug 20, 2027The maintenance fee for Methods of Treating Disease with Levoketoconazole (US 11,903,940) comes due Aug 20, 2027. Unpaid by Feb 22, 2028, it lapses early.
- 1 fee due Sep 29, 2027The maintenance fee for Stable Formulations for Parenteral Injection of Peptide Drugs (US 9,295,724) comes due Sep 29, 2027. Unpaid by Mar 29, 2028, it lapses early.
- 3 fees due Oct 5 to 23, 2027 · next Oct 5
Recent changes
- 1 of the patents on this record was granted since Aug 19, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,110,209 | Intracutaneous Injection In force · High confidence | In force | High confidence | |
| US 8,697,644 | Stable Formulations for Parenteral Injection of Peptide Drugs In force · High confidence | In force | High confidence | |
| US 9,295,724 | Stable Formulations for Parenteral Injection of Peptide Drugs In force · High confidence | In force | High confidence | |
| US 9,302,010 | Stable Formulations for Parenteral Injection of Peptide Drugs In force · High confidence | In force | High confidence | |
| US 9,339,545 | Stable Formulations for Parenteral Injection of Peptide Drugs In force · High confidence | In force | High confidence | |
| US 10,987,399 | Stable Formulations for Parenteral Injection of Peptide Drugs In force · High confidence | In force | High confidence | |
| US 9,138,479 | Formulations for the Treatment of Diabetes In force · High confidence | In force | High confidence | |
| US 9,018,162 | Methods for Rapidly Treating Severe Hypoglycemia In force · High confidence | In force | High confidence | |
| US 9,642,894 | Compositions for Rapidly Treating Severe Hypoglycemia In force · High confidence | In force | High confidence | |
| US 10,765,683 | Stable Formulations for Parenteral Injection of Small Molecule Drugs In force · High confidence | In force | High confidence |
Also on record, not counted in the 29: 1 lapsed for an unpaid fee · 7 ended at full term. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
5 pending · 11 abandoned